Momentum Biotechnologies Completes Strategic Acquisition
Momentum Biotechnologies, a prominent contract research organization (CRO) recognized for its advanced mass spectrometry capabilities, has recently executed a significant acquisition of OmicScouts, a company acclaimed for its expertise in mass spectrometry-based proteomics. This strategic move not only enhances Momentum's service offerings but also marks a pivotal advancement in their objective to remain at the forefront of drug discovery innovations.
A Leap Towards Innovation
Through this acquisition, Momentum Biotechnologies expands its portfolio with a rich array of validated proteomic assays. These enhancements facilitate a more streamlined progression for clients transitioning from high-throughput screening to intricate cell-based assays, including the discovery of new biomarkers and therapeutic targets. Such capabilities are vital in the constantly evolving landscape of biopharmaceutical research.
Can Ozbal, Ph.D., the visionary founder and CEO of Momentum Biotechnologies, highlights that this acquisition addresses a critical need expressed by their clients for deeper insights beyond initial hit identification. With the integration of OmicScouts’ notable chemoproteomic capabilities, the organization aims to effectively fill the current gaps in biochemical triage and downstream assay processes, showcasing an unwavering commitment to scientific excellence.
Expanding Global Reach
The acquisition plays a crucial role in facilitating Momentum's strategic expansion into the European market, thus establishing a broader international presence. By providing top-tier scientific services not just locally but globally, Momentum aims to cater to biopharmaceutical innovators worldwide.
Strong Leadership for Future Growth
In a notable transition, Hannes Hahne, Ph.D., co-founder and CEO of OmicScouts, will now serve as the President and member of Momentum’s global executive leadership team. His profound insights and vision for proteomics-driven drug discovery will be invaluable as the two entities combine their strengths. Hahne emphasizes the shared goals between the teams, highlighting their mutual commitment to making high-throughput mass spectrometry accessible for drug developers.
Aligning Expertise and Client Relationships
The alignment between OmicScouts' and Momentum's strong technical foundations and established client relationships creates a cohesive cultural and operational fit beneficial for both parties. Peter Batesko, Lead Director of Momentum, articulates that the combination leverages OmicScouts' unmatched expertise in the proteomics domain with Momentum's robust screening technologies, ultimately streamlining the drug design process for clients.
Building on a Strong Advisory Foundation
To further enhance their collaborative efforts, Mathias Wilhelm, Ph.D., and Bernhard Kuster, Ph.D., both respected figures in the industry, will join Momentum’s Scientific Advisory Board. Their extensive backgrounds and ongoing commitment to advancing proteomics in therapeutic innovations will provide unique insights crucial for guiding future initiatives. Wilhelm's enthusiasm for the partnership highlights the importance of high-quality mass spectrometry data in drug discovery, while Kuster underscores the potential of proteomics to revolutionize therapeutic advancements.
About Momentum Biotechnologies
Momentum Biotechnologies specializes in delivering cutting-edge mass spectrometry technologies aimed at advancing drug discovery for biopharmaceutical clients globally. Their comprehensive array of services, which includes affinity-selection mass spectrometry (ASMS) and small-molecule analysis, is designed to assist clients in identifying and characterizing pivotal therapeutic leads. With a commitment to rapid and reliable results, Momentum is well-positioned to tackle pressing research questions effectively.
About OmicScouts
OmicScouts stands at the forefront of proteomics, dedicated to aiding drug and biomarker discovery through innovative solutions and comprehensive system-wide assays. Their approach facilitates the pinpointing of small molecule drug targets, enhancing the drug development process with targeted solutions adapted to specific project requirements. This partnership seeks to elevate their collective impact within the pharmaceutical landscape.
Frequently Asked Questions
What is the main significance of the acquisition?
The acquisition enhances Momentum’s service offerings, allowing integration of advanced proteomic assays that improve drug discovery processes for clients.
Who will lead OmicScouts following the acquisition?
Hannes Hahne, co-founder of OmicScouts, will assume the role of President at Momentum Biotechnologies, contributing to the global leadership team.
How does this acquisition affect Momentum's market presence?
This acquisition enables Momentum to expand its operations into the European market, significantly boosting its global footprint in the biopharmaceutical sector.
What technological advancements does OmicScouts bring?
OmicScouts contributes advanced chemoproteomic capabilities and validated proteomic assays, enhancing Momentum's drug discovery toolkit.
What is the future direction for Momentum Biotechnologies after the acquisition?
Momentum aims to leverage the combined expertise to accelerate drug discovery processes and continue innovating in the field of biopharmaceutical research.
